Annual Short Term Debt
$882.00 K
-$70.00 K-7.35%
31 December 2023
Summary:
Lineage Cell Therapeutics annual short term debt is currently $882.00 thousand, with the most recent change of -$70.00 thousand (-7.35%) on 31 December 2023. During the last 3 years, it has fallen by -$403.00 thousand (-31.36%). LCTX annual short term debt is now -67.16% below its all-time high of $2.69 million, reached on 31 December 2003.LCTX Short Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Short Term Debt
$1.14 M
+$22.00 K+1.97%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly short term debt is currently $1.14 million, with the most recent change of +$22.00 thousand (+1.97%) on 30 September 2024. Over the past year, it has increased by +$201.00 thousand (+21.47%). LCTX quarterly short term debt is now -67.69% below its all-time high of $3.52 million, reached on 31 March 2009.LCTX Quarterly Short Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Short Term Debt Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -7.3% | +21.5% |
| 3 y3 years | -31.4% | +39.0% |
| 5 y5 years | +187.3% | -0.1% |
LCTX Short Term Debt High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -31.4% | +6.1% | at high | +100.2% |
| 5 y | 5 years | -31.4% | +187.3% | -35.5% | +100.2% |
| alltime | all time | -67.2% | -67.7% |
Lineage Cell Therapeutics Short Term Debt History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.14 M(+2.0%) |
| June 2024 | - | $1.11 M(+1.3%) |
| Mar 2024 | - | $1.10 M(+24.8%) |
| Dec 2023 | $882.00 K(-7.4%) | $882.00 K(-5.8%) |
| Sept 2023 | - | $936.00 K(-5.2%) |
| June 2023 | - | $987.00 K(+2.5%) |
| Mar 2023 | - | $963.00 K(+1.2%) |
| Dec 2022 | $952.00 K(+14.6%) | $952.00 K(+67.6%) |
| Sept 2022 | - | $568.00 K(-8.7%) |
| June 2022 | - | $622.00 K(-17.1%) |
| Mar 2022 | - | $750.00 K(-9.7%) |
| Dec 2021 | $831.00 K(-35.3%) | $831.00 K(+1.6%) |
| Sept 2021 | - | $818.00 K(+1.4%) |
| June 2021 | - | $807.00 K(-38.3%) |
| Mar 2021 | - | $1.31 M(+1.9%) |
| Dec 2020 | $1.28 M(+5.1%) | $1.28 M(+27.1%) |
| Sept 2020 | - | $1.01 M(-42.7%) |
| June 2020 | - | $1.76 M(+42.3%) |
| Mar 2020 | - | $1.24 M(+1.4%) |
| Dec 2019 | $1.22 M(+298.4%) | $1.22 M(+7.5%) |
| Sept 2019 | - | $1.14 M(+19.0%) |
| June 2019 | - | $956.00 K(-1.6%) |
| Mar 2019 | - | $972.00 K(+216.6%) |
| Dec 2018 | $307.00 K(-15.7%) | $307.00 K(+2.0%) |
| Sept 2018 | - | $301.00 K(-12.8%) |
| June 2018 | - | $345.00 K(+0.9%) |
| Mar 2018 | - | $342.00 K(-6.0%) |
| Dec 2017 | $364.00 K | $364.00 K(+161.9%) |
| Sept 2017 | - | $139.00 K(-94.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2017 | - | $2.68 M(+124.4%) |
| Mar 2017 | - | $1.19 M(+5.3%) |
| Dec 2016 | $1.13 M(+752.6%) | $1.13 M(+81.4%) |
| Sept 2016 | - | $625.00 K(+133.2%) |
| June 2016 | - | $268.00 K(+129.1%) |
| Mar 2016 | - | $117.00 K(-12.0%) |
| Dec 2015 | $133.00 K(+129.3%) | $133.00 K(-66.4%) |
| Sept 2015 | - | $396.00 K(+33.8%) |
| June 2015 | - | $296.00 K(+30.2%) |
| Mar 2015 | - | $227.40 K(+292.1%) |
| Dec 2014 | $58.00 K(>+9900.0%) | $58.00 K(-4.3%) |
| Sept 2014 | - | $60.60 K(+5.4%) |
| June 2014 | - | $57.50 K(>+9900.0%) |
| Dec 2013 | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2009 | - | $135.50 K(-95.9%) |
| June 2009 | - | $3.31 M(-5.8%) |
| Mar 2009 | - | $3.52 M(>+9900.0%) |
| Dec 2008 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sept 2008 | - | $2.69 M(+39.8%) |
| June 2008 | - | $1.92 M(+47.2%) |
| Mar 2008 | - | $1.31 M(+82.5%) |
| Dec 2007 | $716.50 K(-73.3%) | $716.50 K(+102.5%) |
| Sept 2007 | - | $353.90 K(+15.5%) |
| June 2007 | - | $306.40 K(+206.4%) |
| Mar 2007 | - | $100.00 K(-96.3%) |
| Dec 2003 | $2.69 M | $2.69 M(+9.4%) |
| Sept 2003 | - | $2.45 M(-26.7%) |
| Sept 2001 | - | $3.35 M(+570.0%) |
| June 2001 | - | $500.00 K |
FAQ
- What is Lineage Cell Therapeutics annual short term debt?
- What is the all time high annual short term debt for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual short term debt year-on-year change?
- What is Lineage Cell Therapeutics quarterly short term debt?
- What is the all time high quarterly short term debt for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly short term debt year-on-year change?
What is Lineage Cell Therapeutics annual short term debt?
The current annual short term debt of LCTX is $882.00 K
What is the all time high annual short term debt for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual short term debt is $2.69 M
What is Lineage Cell Therapeutics annual short term debt year-on-year change?
Over the past year, LCTX annual short term debt has changed by -$70.00 K (-7.35%)
What is Lineage Cell Therapeutics quarterly short term debt?
The current quarterly short term debt of LCTX is $1.14 M
What is the all time high quarterly short term debt for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly short term debt is $3.52 M
What is Lineage Cell Therapeutics quarterly short term debt year-on-year change?
Over the past year, LCTX quarterly short term debt has changed by +$201.00 K (+21.47%)